Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects

British Journal of Clinical Pharmacology

Volumn 59, Issue 1, 2005, Pages 38-42

  Boffito, Marta ^a   Back, David ^b   Stainsby Tron, Meredith ^b   Hill, Andrew ^b,c   Di Perri, Giovanni ^d   Moyle, Graeme ^a   Nelson, Mark ^a   Tomkins, Jaqui ^a   Gazzard, Brian ^a   Pozniak, Anton ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c University of Turin ^*

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Antiretroviral drugs; Drug interactions; Saquinavir ritonavir; Tenofovir

Indexed keywords

RITONAVIR; SAQUINAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MIXTURE; GEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; TIME TO REACH MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET RADIATION;

EID: 19944377562     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02240.x     Document Type: Article

References (19)

1. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16(Suppl 1): S5.
2. Kaul S, Bassi K, Damle B, et al. Pharmacokinetic evaluation of the combination of atazinavir (ATV), enteric coated didanosine (ddl-EC), and tenofovir disoproxil fumurate (TDF) for a once-daily antiretroviral regime. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2003, Abstract A-1616.
3. Kearney B, Mittan A, Sayre J, et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2003, Abstract A-1617.
4. Poirier J, Meynard J, Guiard-Schmid J, Girard P, Rozenbaum W, Jaillon P. Lack of alteration of lopinavir and ritonavir trough plasma concentrations in HIV-experienced patients treated with Kaletra and tenofovir DF. 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 2002, Abstract H-1715.
5. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999; 36: 127-43.
6. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999; 56: 383-9.
7. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40: 1331-3.
8. Coca S, Perazella MA. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324: 342-4.
9. Créput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patients treated with tenofovir. AIDS 2003; 17: 935-7.
10. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070-3.
11. Murphy MD, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003; 36: 1082-5.
12. The Adult AIDS Clinical Trials Group (AACTG): http://aactg.s-3.com.
13. Reynolds HE, Tjia JF, Gibbons SE, Khoo SH, Back DJ. Simultaneous determination of four HIV protease inhibitors by HPLC-MS/MS for use in a therapeutic drug monitoring service. Br J Clin Pharmacol 2001; 52: 481P-482P.
14. D'Avolio A, Sciandra M, Bonora S, et al. An optimised solid phase extraction (SPE) method to quantify tenofovir in human plasma. 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, 2004: Abstract, 8.2.
15. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med, 2001; 344: 984-96.
16. Antoniou T, Park-Wyllie LY, Tseng AL. Tenofovir, a nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy 2003; 23: 29-43.
17. Flaherty J, Kearney B, Wolf J, Sayre J, Coakley D. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and efavirenz, indinavir, or lopinavir/ritonavir. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, 2001: Abstract 336.
18. Boffito M, Back DJ, Hoggard PG, et al. Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. AIDS 2003; 17: 1107-8.
19. Back D, Blaschke T, Boucher C, et al. Optimising TDM in HIV. clinical care: a practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents. Version 1.0 2003. Available at: http://www. hivpharmacology.com/.